The PACIFIC Trial in Stage 3 NSCLC
The original presentation, which is now published in the *New England Journal of Medicine*, showed a remarkable improvement in progression‑free survival 16.8 months versus 5.6 months
Durvalumab consolidation after chemoradiation markedly extends progression‑free survival in stage III NSCLC, providing the first randomized evidence of a survival advantage in this setting and reshaping standard care
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT